Lercanidipina Ratiopharm (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels in the smooth muscle of blood vessels. This inhibition prevents calcium‑mediated contraction, leading to vasodilation of peripheral arteries, a decrease in systemic vascular resistance, and ultimately a reduction in arterial blood pressure.

The appropriate dose of lercanidipine is determined by the prescribing healthcare professional based on the individual’s blood pressure, response to therapy, and any co‑existing medical conditions. The prescriber will select the starting dose and may adjust it according to therapeutic goals and tolerability.

Safety of lercanidipine in pregnancy and lactation has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To request Lercanidipina Ratiopharm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including any required temperature control) and assists with import documentation.

Both lercanidipine and amlodipine belong to the dihydropyridine class and lower blood pressure by vasodilation. Lercanidipine has a longer half‑life and may provide smoother blood‑pressure control with a lower incidence of reflex tachycardia, whereas amlodipine is widely used and has an extensive safety record. Choice of therapy depends on patient‑specific factors and clinician preference.

Store Lercanidipina Ratiopharm at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight to maintain potency throughout the shelf‑life.

Lercanidipina Ratiopharm is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional and not alter the dose without medical advice.

Serious adverse events, although uncommon, include severe hypotension, angioedema, myocardial infarction, and hepatic dysfunction. Patients should seek immediate medical attention if they experience symptoms such as sudden dizziness, swelling of the face or throat, chest pain, or signs of liver injury.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation. It should be used with caution in individuals with severe hepatic impairment, unstable angina, or a history of significant hypotension. A healthcare professional must evaluate suitability before initiating therapy.